Cumberland Pharmaceuticals Inc (NASDAQ: CPIX) a specialty pharmaceutical company, has started an initiative to increase availability of Vaprisol (conivaptan hydrochloride) injection intended to treat hyponatremia, associated with critical care patients during the COVID-19 pandemic, it was reported on Tuesday.

The product is a US FDA approved treatment for hyponatremia, a potentially life-threatening condition that causes critically low sodium levels and that can often afflict patients in the Intensive Care Unit.

The company's initiative includes special supply and financial arrangements, including favourable pricing and payment terms, for hospitals and clinics to help ensure timely access to Vaprisol during this healthcare crisis.